Wealthfront Advisers’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.57M | Buy |
16,529
+850
| +5% | +$163K | 0.01% | 504 |
|
|
2026
Q1 | $2.87M | Buy |
15,679
+128
| +0.8% | +$23.6K | 0.01% | 543 |
|
|
2025
Q4 | $2.74M | Buy |
15,551
+4,227
| +37% | +$691K | 0.01% | 536 |
|
|
2025
Q3 | $1.59M | Buy |
11,324
+2,640
| +30% | +$357K | ﹤0.01% | 622 |
|
|
2025
Q2 | $1.09M | Buy |
8,684
+4,899
| +129% | +$610K | ﹤0.01% | 664 |
|
|
2025
Q1 | $518K | Buy |
3,785
+1,949
| +106% | +$279K | ﹤0.01% | 773 |
|
|
2024
Q4 | $281K | Sell |
1,836
-1,316
| -42% | -$222K | ﹤0.01% | 844 |
|
|
2024
Q3 | $611K | Sell |
3,152
-371
| -11% | -$77.6K | ﹤0.01% | 736 |
|
|
2024
Q2 | $817K | Sell |
3,523
-2,138
| -38% | -$465K | ﹤0.01% | 662 |
|
|
2024
Q1 | $1.22M | Sell |
5,661
-271
| -5% | -$63.5K | ﹤0.01% | 576 |
|
|
2023
Q4 | $1.54M | Buy |
5,932
+332
| +6% | +$81.5K | 0.01% | 512 |
|
|
2023
Q3 | $1.44M | Sell |
5,600
-4,941
| -47% | -$1.32M | 0.01% | 488 |
|
|
2023
Q2 | $3M | Buy |
10,541
+205
| +2% | +$61K | 0.01% | 325 |
|
|
2023
Q1 | $2.87M | Buy |
10,336
+3,825
| +59% | +$1.06M | 0.01% | 331 |
|
|
2022
Q4 | $1.8M | Buy |
6,511
+133
| +2% | +$37.6K | 0.01% | 427 |
|
|
2022
Q3 | $1.7M | Buy |
6,378
+1,869
| +41% | +$397K | 0.01% | 397 |
|
|
2022
Q2 | $920K | Sell |
4,509
-5,526
| -55% | -$1.13M | ﹤0.01% | 499 |
|
|
2022
Q1 | $2.11M | Buy |
10,035
+7,508
| +297% | +$1.63M | 0.01% | 387 |
|
|
2021
Q4 | $606K | Sell |
2,527
-8,077
| -76% | -$2.08M | ﹤0.01% | 565 |
|
|
2021
Q3 | $3M | Sell |
10,604
-169
| -2% | -$55.4K | 0.01% | 253 |
|
|
2021
Q2 | $3.73M | Buy |
10,773
+1,572
| +17% | +$476K | 0.02% | 172 |
|
|
2021
Q1 | $2.57M | Buy |
9,201
+2,872
| +45% | +$775K | 0.01% | 213 |
|
|
2020
Q4 | $1.55M | Buy |
6,329
+550
| +10% | +$142K | 0.01% | 286 |
|
|
2020
Q3 | $1.64M | Sell |
5,779
-2,154
| -27% | -$601K | 0.01% | 222 |
|
|
2020
Q2 | $2.12M | Sell |
7,933
-1,974
| -20% | -$593K | 0.02% | 156 |
|
|
2020
Q1 | $3.13M | Buy |
9,907
+1,265
| +15% | +$384K | 0.03% | 95 |
|
|
2019
Q4 | $2.56M | Buy |
8,642
+3,986
| +86% | +$1.11M | 0.02% | 136 |
|
|
2019
Q3 | $1.08M | Buy |
4,656
+201
| +5% | +$46.8K | 0.01% | 278 |
|
|
2019
Q2 | $1.04M | Buy |
4,455
+2,658
| +148% | +$614K | 0.01% | 267 |
|
|
2019
Q1 | $425K | Sell |
1,797
-7,201
| -80% | -$2.27M | ﹤0.01% | 382 |
|
|
2018
Q4 | $2.71M | Buy |
+8,998
| New | +$2.87M | 0.03% | 100 |
|
Other funds holding BIIB
Wealthfront Advisers's BIIB Position: Q2 2026 in Review
Wealthfront Advisers increased its Biogen (BIIB) stake by 5.4% in Q2 2026, buying an estimated $163K and bringing the position to 16,529 shares worth $3.57M. The position accounts for 0.01% of the portfolio, ranked #504.
Wealthfront Advisers first reported a position in BIIB in Q4 2018 and has held it in 31 quarters since. The position peaked at $3.73M in Q2 2021. 772 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Wealthfront Advisers held 16,529 shares of Biogen worth $3.57M as of Q2 2026.
- Wealthfront Advisers bought 850 Biogen shares in Q2 2026, an estimated $163K.
- Biogen made up 0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #504 holding.
- Wealthfront Advisers first reported a position in Biogen in Q4 2018 and has held it in 31 quarters since.
- Wealthfront Advisers's Biogen position peaked at $3.73M in Q2 2021.
- 772 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.